INHALEABILITY FORUM
Revealing the role of tiotropium in severity and control of pediatric asthma
Asthma is a serious health problem among children, young people died of asthma from time to time. Clarifying the severity of asthma regarding acute exacerbation and control are the target of asthma management. In the 2022 updates of Global Initiative for Asthma (GINA) guidelines, severity characterization and corresponding stepwise management were proposed to control symptoms and minimize the risk of asthma-related mortality, exacerbations, and persistent airflow limitations while limiting treatment-related side effects.1 According to the GINA guidelines, tiotropium, a long-acting muscarinic antagonist (LAMA), is recommended to be added in the management of severe persistent asthma in individuals, based on its statistically significant benefits in control of severe asthma demonstrated in 18 trials with more than 6,000 young and adult patients compared with placebo.1-3 To maximize the treatment outcome, an optimal inhaler device or spacer device should be adopted to deliver desired and consistent therapeutic effects.
In this video, Dr. Hon Kam-Lun Ellis of the Chinese University of Hong Kong discussed his view on the severity of asthma control and the current recommendation for managing asthma to control symptoms and minimize the risk of asthma-related mortality by the GINA guidelines. He also shared the two trials that have proven significant benefits of tiotropium usage on pediatric asthma.
